BioSpace News Archive

Helix Biopharma announce that together with its wholly-owned subsidiary Helix Immuno-Oncology, it will present a poster entitled: Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models at the American Association for Cancer Research (“AACR”) Annual Meeting 2018 which is taking place on April 14 - 18, 2018 at McCormick Place in Chicago, Illinois.

Two clinical trial sites are currently screening and enrolling patients and five additional sites are planned to be activated by the end of the first quarter.

The company will also provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time.

The multi-year partnership, which began Jan. 1, 2018, represents a significant step in the United States-based company’s overseas growth, as many of BioGX’s products will now be available to a considerably broader customer base.

The Q is the industry’s smallest, fastest, best performing, and most affordable cycler, making it ideal for all molecular testing applications.

The proceeds of the offering are expected to be used primarily for the Phase 2 PISCES/KEYNOTE-695 trial in melanoma, for other clinical and research and development activities, and for working capital and general corporate purposes.

Investment to fund commercialization and development of the game changing Machine-vision Image Guided Surgery (MvIGS) technology [06-February-2018] TORONTO, Feb. 6, 2018 /PRNewswire/ -- 7D Surgical is pleased to announce the completion of the largest round of financing secured by the company to date, providing the funding necessary to support the commercial l

Targeted therapies create new opportunities for patients, but can require complex trial design to achieve their promise.

He will be based out of MannKind’s Westlake Village, California headquarters.

PharmaCyte today announced that the steps necessary for the testing of cells from its Master Cell Bank (MCB) have been completed by Eurofins Lancaster Laboratories and that testing began last month.